STAT

The NIH is squandering an opportunity to fund more researchers

The NIH shouldn't abandon a research funding plan that would create more scientific breakthroughs and help train the next generation of researchers.
Source: Lydia Polimeni/NIH

This spring, the National Institutes of Health announced a dramatic change to the way it would support biomedical research in the United States. NIH Director Francis Collins offered a bold new approach called the Grant Support Index (GSI) that would bolster funding to early-career researchers and limit the number of major NIH research projects that any individual could oversee to three. This approach to funding was proposed in part to grow a larger research community, and in part to ensure that individual researchers were able to responsibly oversee their funded work.

But then Collins — essentially the current flawed system — was in.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related